Wednesday 24 April 2024
Internal Reference Number: FOI_6871
Date Request Received: 15/11/2022 00:00:00
Date Request Replied To: 29/11/2022 00:00:00
This response was sent via: By Email
Request Summary: Oesophageal and Gastric Cancer
Request Category: Researcher
| Question Number 1: Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for: • Oesophageal cancer (any type or stage) • Oesophageal adenocarcinoma (any stage) • Oesophageal squamous cell carcinoma (any stage) • Gastric cancer (any type or stage) • Cancer of the gastro-oesophageal junction (any stage) | |
| Answer To Question 1: • Oesophageal cancer (any type or stage) August 2022 - <=5 September 2022 – 6 October 2022 <=5 • Oesophageal adenocarcinoma (any stage) August 2022 - <=5 September 2022 - <=5 – October 2022 0 • Oesophageal squamous cell carcinoma (any stage) August 2022 -<=5 September 2022 <=5 – October 2022 <=5 • Gastric cancer (any type or stage) August 2022 - <=5 September 2022 <=5 – October 2022 <=5 • Cancer of the gastro-oesophageal junction (any stage) August 2022 - <=5 September 2022 <=5 – October 2022 <=5 | |
| Question Number 2: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 2: • CAPOX (Capecitabine with Oxaliplatin) 7 • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <=5 • Lonsurf (Trifluridine - tipiracil) <=5 • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <=5 • Any other systemic anti-cancer therapy <=5 • Palliative care only <=5 | |
| Question Number 3: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Nivolumab monotherapy • Nivolumab and Ipilimumab • Any other systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 3: • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) <=5 • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) <=5 • Nivolumab monotherapy 0 • Nivolumab and Ipilimumab 0 • Any other systemic anti-cancer therapy <=5 • Palliative care only <=5 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
